Penile traction therapy with the new device ‘Penimaster PRO ’ is effective and safe in the stable phase of Peyronie's disease: a controlled multicentre study
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Objectives: To evaluate the efficacy and safety of a new penile traction device ( PTD ), ‘Penimaster PRO ’, in a group of patients with stable Peyronie's disease ( PD ) compared with a non‐intervention group in a multicentre study. Material and Methods: A total of 93 patients with chronic stable PD (without erectile dysfunction, with no significant pain, and with a unidirectional curvature of at least 45° being stable for > 3 months) were recruited and followed for a 12‐week period. Of these patients, 47 were randomly assigned to the Penimaster PRO group ( PG ) and 46 to the non‐intervention group ( NIG ). Patients were asked to apply the PTD 3–8 h a day for 12 consecutive weeks, with specific instructions regarding the progressive increase of traction force applied to the penis over time. The primary outcome of the study was the change in the degree of curvature measured in the fully erect state after intracavernosal injection of alprostadil at baseline, 1, 2 and 3 months. Other variables, such as the type of curvature, stretched penile length ( SPL ), Peyronie's Disease Questionnaire ( PDQ ) scores, erectile function domain of the International Index of Erectile function ( IIEF ‐ EF ) score and adverse events (AEs) were also assessed in each visit. Results: Forty‐one patients in the PG and 39 in the NIG completed the study. There was an overall reduction in curvature of 31.2° ( P < 0.001) at 12 weeks compared to baseline in the PG , representing a 41.1% improvement from baseline, which significantly correlated with the number of daily hours the device was applied in a dose‐dependent manner. Those patients using the device < 4 h/day experienced a reduction of 15°–25° (mean 19.7°, 28.8% improvement; P < 0.05), while patients using the device > 6 h/day experienced greater curvature reduction, ranging from 20° to 50° (mean of 38.4°, 51.4% improvement; P < 0.001). In contrast, no significant changes in curvature were observed in the NIG . Furthermore, SPL increased significantly in the PG compared to baseline and compared with the NIG , ranging from 0.5 to 3.0 cm (mean 1.8 cm; P < 0.05). The IIEF ‐ EF score also improved in patients in the PG (by a mean of 5 points). Mild AEs occurred in 43% of patients, such as local discomfort and glans numbness. Conclusion: The use of the Penimaster PRO PTD , a non‐invasive treatment, should be offered to patients with stable PD for 3 consecutive months before performing any corrective surgery, as this provided a significant reduction in the curvature, an increase in penile length and a significant improvement of the symptoms and bother induced by PD .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peyronie’s Disease: AUA Guideline
Nehra, A., Alterowitz, R., Culkin, D. J., Faraday, M. M., Hakim, L. S., Heidelbaugh, J. J., Khera, M., Kirkby, E., McVary, K. T., Miner, M. M., et al. (2015) · Journal of Urology · doi:10.1016/j.juro.2015.05.098 · Cited by 416
Cited by
Salonia, A., Capogrosso, P., Boeri, L., Cocci, A., Corona, G., Dinkelman-Smit, M., Falcone, M., Jensen, C. F., Gül, M., Kalkanli, A., et al. (2025) · European Urology · doi:10.1016/j.eururo.2025.04.010 · Cited by 174
Self-citationPeyronie’s disease: Contemporary evaluation and management
Ziegelmann, M. J., Bajic, P., & Levine, L. A. (2020) · International Journal of Urology · doi:10.1111/iju.14230 · Cited by 86
Self-citationPeyronie’s disease: pharmacological treatments and limitations
Li, E. V., Esterquest, R., Pham, M. N., Panken, E. J., Amarasekera, C., Siebert, A., Bajic, P., & Levine, L. A. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1903873 · Cited by 24
Self-citationNon-surgical therapies for Peyronie’s disease
Rosenberg, J. E., Ergun, O., Hwang, E. C., Risk, M. C., Jung, J. H., Edwards, M. E., Blair, Y., & Dahm, P. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012206.pub2 · Cited by 14
Current trends in non‐surgical management of Peyronie's disease—A narrative review
Kozub, A., Suleja, A., Chłosta, M., Kupilas, A., Pradere, B., Rivas, J. G., Rajwa, P., & Miszczyk, M. (2024) · Andrology · doi:10.1111/andr.13512 · Cited by 5
Metadata
- Authors
- Moncada, I., Krishnappa, P., Romero, J., Torremade, J., Fraile, A., Martinez‐Salamanca, J. I., Porst, H., & Levine, L.
- Venue
- BJU International
- Publisher
- Wiley
- Published
- 2018-11-22
- Volume
- 123
- Issue
- 4
- Pages
- 694-702
- ISSN
- 1464-4096 (ISSN-L)
- 1464-410X
- OpenAlex
- W2898295222
- Cited by
- 69
- References
- 1
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.